Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research in the area of breast cancer reported from C. Dalessandro and colleagues
October 23rd, 2008
According to recent research from Milan, Italy, "We analyzed the role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy. Thirty-eight patients (estrogen receptor [ER] and/or progesterone receptor [PgR] >= 10% of the cells 21, premenopausal 14, Ki-67 expression >= 20% of the cells 30, HER2/neu overexpressed 11) were treated with six courses of epirubicin, cisplatin and fluorouracil (FU) as continuous infusion, perioperative FU as continuous infusion, mastectomy and loco-regional radiotherapy." "In endocrine-responsive patients, endocrine treatment (letrozole, either alone or if...
Source: Women's Health Weekly (2008-10-23)
|
